458 related articles for article (PubMed ID: 19002120)
1. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
3. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.
Shim HB; Lee JK; Jung TY; Ku JH
Prostate Cancer Prostatic Dis; 2007; 10(2):143-8. PubMed ID: 17199133
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
[TBL] [Abstract][Full Text] [Related]
5. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
6. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
7. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between serum PSA and prostate volume in benign hyperplasia].
Ojea Calvo A; Rodrigo AA; Verez Vivero MM; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; Nogueira March JL
Actas Urol Esp; 1994 Mar; 18(3):178-80. PubMed ID: 7518640
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
Lowe FC; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; O'Leary M; Perez M; Speakman M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
Prostate Cancer Prostatic Dis; 2005; 8(3):206-9. PubMed ID: 15953934
[TBL] [Abstract][Full Text] [Related]
10. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
Trachtenberg J
BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
[TBL] [Abstract][Full Text] [Related]
11. Definition of at-risk patients: dynamic variables.
Emberton M
BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
[TBL] [Abstract][Full Text] [Related]
12. Definition of at-risk patients: baseline variables.
Roehrborn CG
BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
14. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia.
Lee SE; Chung JS; Han BK; Moon KH; Hwang SI; Lee HJ; Choe G; Hong SK
Urology; 2008 Mar; 71(3):395-8. PubMed ID: 18342171
[TBL] [Abstract][Full Text] [Related]
15. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
Hall MC; Roehrborn CG; McConnell JD
Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of benign prostatic hyperplasia with hyperlipemia].
Li PJ; Zhang XH; Guo LJ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
[TBL] [Abstract][Full Text] [Related]
17. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
18. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study.
Bosch JL; Bohnen AM; Groeneveld FP
Eur Urol; 2004 Dec; 46(6):753-9. PubMed ID: 15548443
[TBL] [Abstract][Full Text] [Related]
19. Prevention of benign prostatic hyperplasia disease.
Marks LS; Roehrborn CG; Andriole GL
J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of prostatic-specific antigen levels in patients with benign prostatic hyperplasia complicated by low urinary tract syndrome].
Zhu YJ; Ye M; Wang WM; Shen HB; Chen JH; Chen F
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):156-8. PubMed ID: 16519156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
